Correction: Genomic EWSR1 fusion sequence as highly sensitive and dynamic plasma tumor marker in ewing sarcoma (Clinical Cancer Research (2016) 22 (4356-4365) DOI: 10.1158/1078-0432.CCR-15-3028);Genomic EWSR1 fusion sequence as highly sensitive and dynamic plasma tumor marker in ewing sarcoma

Clinical Cancer Research

Volumn 22, Issue 17, 2016, Pages 4356-4365

  Krumbholz, Manuela ^a   Hellberg, Julia ^a   Steif, Benedikt ^a   Bäuerle, Tobias ^a   Gillmann, Clarissa ^a   Fritscher, Torsten ^a   Agaimy, Abbas ^a   Frey, Benjamin ^a   Juengert, Joerg ^a   Wardelmann, Eva ^b   Hartmann, Wolfgang ^b   Juergens, Heribert ^b   Dirksen, Uta ^b   Metzler, Markus ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE TUMOR DNA; DNA; TUMOR MARKER; UNCLASSIFIED DRUG; EWSR1-FLI1 FUSION PROTEIN, HUMAN; ONCOPROTEIN; RNA BINDING PROTEIN EWS;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CANCER LOCALIZATION; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EWING SARCOMA; EWSR1 GENE; FEMALE; FLI1 GENE; GENE; GENE DOSAGE; GENE FUSION; GENE SEQUENCE; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA VOLUME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TUMOR DIFFERENTIATION; TUMOR VOLUME; ADOLESCENT; ANIMAL; BLOOD; CHILD; DISEASE MODEL; GENE TRANSLOCATION; GENETICS; KNOCKOUT MOUSE; LIQUID BIOPSY; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; DNA, NEOPLASM; FEMALE; HUMANS; LIQUID BIOPSY; MALE; MICE; MICE, KNOCKOUT; ONCOGENE PROTEINS, FUSION; POSITRON-EMISSION TOMOGRAPHY; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; SENSITIVITY AND SPECIFICITY; TRANSLOCATION, GENETIC; TUMOR BURDEN; YOUNG ADULT;

EID: 84988674562     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2685     Document Type: Erratum

References (36)

1. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, et al. Ewing's sarcoma family of tumors: Current management. Oncologist 2006;11:503-19.
2. Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, et al. Ewing sarcoma: Current management and future approaches through collaboration. J Clin Oncol 2015;33:3036-46.
3. Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: Results of the Euro-EWING 99 trial. J Clin Oncol 2010;28:3284-91.
4. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
5. Sankar S, Lessnick SL. Promiscuous partnerships in Ewing's sarcoma. Cancer Genet 2011;204:351-65.
6. Antonescu C. Round cell sarcomas beyond Ewing: Emerging entities. Histopathology 2014;64:26-37.
7. Schwarzenbach H, Eichelser C, Kropidlowski J, Janni W, Rack B, Pantel K. Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. Clin Cancer Res 2012;18:5719-30.
8. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
9. Bazan V, Bruno L, Augello C, Agnese V, Calo V, Corsale S, et al. Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Ann Oncol 2006;17 Suppl 7:vii84-90.
10. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14: 985-90.
11. Garcia JM, Garcia V, Silva J, Pena C, Dominguez G, Sanchez A, et al. Extracellular tumor DNA in plasma and overall survival in breast cancer patients. Genes Chromosomes Cancer 2006;45:692-701.
12. Andriani F, Conte D, Mastrangelo T, Leon M, Ratcliffe C, Roz L, et al. Detecting lung cancer in plasma with the use of multiple genetic markers. Int J Cancer 2004;108:91-6.
13. Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov 2014;4:1326-41.
14. Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 2014;4:1342-53.
15. Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet 2014;10:e1004475.
16. Agelopoulos K, Richter GH, Schmidt E, Dirksen U, von Heyking K, Moser B, et al. Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in Ewing sarcoma. Clin Cancer Res 2015;21:4935-46.
17. Van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009;23:1073-9.
18. Van Valen F. Ewing's sarcoma family of tumors. In: Masters JRW, Palsson BO, editors. Human cell culture 1. Great Britain: Kluwer; 1998. pp. 55-85.
19. Berger M, Dirksen U, Braeuninger A, Koehler G, Juergens H, Krumbholz M, et al. Genomic EWS-FLI1 fusion sequences in Ewing sarcoma resemble breakpoint characteristics of immature lymphoid malignancies. PLoS One 2013;8:e56408.
20. Lin PP, Brody RI, Hamelin AC, Bradner JE, Healey JH, Ladanyi M. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res 1999;59:1428-32.
21. Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 2010;28:1982-8.
22. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426-37.
23. Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanche H, et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res 2014;20:4613-24.
24. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
25. Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 2015;21:3196-203.
26. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502:333-9.
27. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007;7:233-45.
28. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 2013;499:214-8.
29. Gamberi G, Cocchi S, Benini S, Magagnoli G, Morandi L, Kreshak J, et al. Molecular diagnosis in Ewing family tumors: The Rizzoli experience-222 consecutive cases in four years. J Mol Diagn 2011;13:313-24.
30. Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced nonsmall cell lung cancer during treatment with erlotinib. Cancer 2014;120: 3896-901.
31. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 2014;6:224ra26.
32. Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, et al. Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration. Clin Cancer Res 2015;21:4586-96.
33. Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 2015;125:3679-87.
34. Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: A correlative biomarker study. Lancet Oncol 2015;16:541-9.
35. Rasper M, Jabar S, Ranft A, Jurgens H, Amler S, Dirksen U. The value of highdose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer 2014;61:1382-6.
36. Stahl M, Ranft A, Paulussen M, Bolling T, Vieth V, Bielack S, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011;57:549-53.